Application of a chymase inhibitor, NK3201, for prevention of vascular proliferation

Cardiovascular Drug Reviews

Volumn 21, Issue 3, 2003, Pages 185-198

  Takai, Shinji ^a   Miyazaki, Mizuo ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Angiotensin; Chymase; Chymase inhibitors; NK3201; Vascular proliferation

Indexed keywords

2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; 4 [1 [[BIS (4 METHYLPHENYL)METHYL]CARBAMOYL] 3 (2 ETHOXYBENZYL) 4 OXOAZETIDIN 2 YLOXY]BENZOIC ACID; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; CHYMASE; CHYMASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ELASTASE; ENALAPRIL; ENZYME INHIBITOR; N [1 BENZYL 2,3 DIOXO 6 (2 PYRIDYLOXY)HEXYL] 2 (5 FORMYLAMINO 1,6 DIHYDRO 6 OXO 2 PHENYL 1 PYRIMIDINYL)ACETAMIDE; PLASMIN; PLASMINOGEN ACTIVATOR; SERINE PROTEINASE; THROMBIN; TRANSFORMING GROWTH FACTOR BETA; TRYPTASE; UNCLASSIFIED DRUG;

BALLOON DILATATION; BLOOD PRESSURE; BLOOD VESSEL; BLOOD VESSEL INJURY; BLOOD VESSEL PROLIFERATION; CELL PROLIFERATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TISSUE LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HYPERTENSION; IC 50; MAST CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; TOXICITY TESTING; VEIN GRAFT;

EID: 0141885364     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2003.tb00115.x     Document Type: Review

References (57)

1. Araujo GW, Pesquero JB, Lindsey CJ, Paiva AC, Pesquero JL. Identification of serine proteinases with tonin-like activity in the rat submandibular and prostate glands. Biochim Biophys Acta 1991;1074:167-171.
2. Borland JA, Chester AH, Crabbe S, Parkerson JB, Catravas JD, Yacoub MH. Differential action of angiotensin II and activity of angiotensin-converting enzyme in human bypass grafts. J Thorac Cardiovasc Surg 1998;116:206-212.
3. Boucher R, Demassieux S, Garcia R, Genest J. Tonin, angiotensin 11 system. Circ Res 1977;41(4, Suppl 2): 26-29.
4. Caughey GH, Raymond WW, Wolters PJ. Angiotensin II generation by mast cell alpha- and beta-chymases. Biochim Biophys Acta 2000;1480:245-257.
5. Chamberlain J. Transforming growth factor-beta: A promising target for anti-stenosis therapy. Cardiovasc Drug Rev 2001;19:329-434.
6. Craig SS, Schwartz LB. Human MCTC type of mast cell granule: The uncommon occurrence of discrete scrolls associated with focal absence of chymase. Lab Invest 1990;63:581-585.
7. Faxon DP. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: Final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. J Am Coll Cardiol 1995;2:362-369.
8. Fuchs JC, Mitchener JS, Hagen PO. Postoperative changes in autologous vein grafts. Ann Surg 1978;188: 1-15.
9. Fukuyama J, Ichikawa K, Miyazawa K, Hamano S, Shibata N, Ujiie A. Tranilast suppresses intimal hyperplasia in the balloon injury model and cuff treatment model in rabbits. Jpn J Pharmacol 1996;70:321-327.
10. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin 11. J Clin Invest 1992; 90:456-461.
11. Goldstein SM, Kaempfer CE, Kealey JT, Wintroub BU. Human mast cell carboxypeptidase. J Clin Invest 1989;83:1630-1636.
12. Goldstein SM, Kaempfer CE, Proud D, Schwartz LB, Irani A, Wintroub BU. Detection and partial characterization of a human mast cell carboxypeptidase. J Immunol 1987;139:2724-2729.
13. Green GE, Stertzer SH, Reppert EH. Coronary arterial bypass grafts. Ann Thorac Surg 1968;5:443-450.
14. Hanson SR, Powell JS, Dodson T, et al. Effects of angiotensin converting enzyme inhibition with cilazapril on intimal hyperplasia in injured arteries and vascular grafts in the baboon. Hypertension 1991;18(Suppl 4): 1170-1176.
15. Holmes DR Jr, Savage M, LaBlanche JM, et al. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2002;106:1243-1250.
16. Jin D, Takai S, Shiota N, Miyazaki M. Roles of vascular angiotensin converting enzyme and chymase in two-kidney, one clip hypertensive hamsters. J Hypertens 1998; 16:657-664.
17. Kauffman RF, Bean JS, Zimmerman KM, Brown RF, Steinberg MI. Losartan, a nonpeptide angiotensin 11 (Ang 11) receptor antagonist, inhibits neointima formation following balloon injury to rat carotid arteries. Life Sci 1991;49:PL223-PL228.
18. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin 11-mediated cardiovascular and renal diseases. Pharmacol Rev 2000;52:11-34.
19. Koda A, Kurashina Y, Nakazawa M. The inhibition mechanism of histamine release by N-(3,4-dimethoxycinnamoyl) anthranilic acid. Int Arch Allergy Appl Immunol 1985;77:244-245.
20. Kokkonen JO, Saarinen J, Kovanen PT. Regulation of local angiotensin 11 formation in the human heart in the presence of interstitial fluid. Inhibition of chymase by protease inhibitors of interstitial fluid and of angiotensin-converting enzyme by Ang-(1-9) formed by heart carboxypeptidase A-like activity. Circulation 1997;95:1455-1463.
21. Kuwahara F, Kai H, Tokuda K, et al. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002;106:130-135.
22. Lytle BW, Loop FD, Cosgrove DM, Ratliff NB, Easley K, Taylor PC. Long-term (5 to 12 years) serial studies of internal mammary artery and saphenous vein coronary bypass grafts. J Thorac Cardiovasc Surg 1985;89:248-258.
23. McEuen AR, Sharma B, Walls AF. Regulation of the activity of human chymase during storage and release from mast cells: The contributions of inorganic cations, pH, hepafin and histamine. Biochim Biophys Acta 1995;1267:115-121.
24. MERCATOR Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Circulation 1992;86:100-110.
25. Miyazaki M, Okamura T, Okunishi H, Toda N. Vascular angiotensin converting enzyme in the development of renal hypertension. J Cardiovasc Pharmacol 1986;8(Suppl 10):S58-S61.
26. Miyazaki M, Shiota N, Sakonjo H, Takai S. Angiotensin II type 1 receptor antagonist, TCV-116, prevents neointima formation in injured arteries in the dog. Jpn J Pharmacol 1999;79:455-460.
27. Miyazaki M, Wada T, Shiota N, Takai S. Effect of an angiotensin II receptor antagonist, candesartan cilexetil, on canine intima hyperplasia after balloon injury. J Hum Hypertens 1999;13(Suppl 1):S21-S25.
28. Nakamura F, Nagano M, Kobayashi R, et al. Chronic administration of angiotensin II receptor antagonist, TCV-116, in cardiomyopathic hamsters. Am J Physiol 1994;267:H2297-H2304.
29. Nakamura Y, Nakamura K, Matsukura T, Nakamura K. Vascular angiotensin converting activity in spontaneously hypertensive rats and its inhibition with cilazapril. J Hypertens 1988;6:105-110.
30. Nishimoto M, Takai S, Kim S, et al: Significance of chymase-dependent angiotensin II-forming pathway in the development of vascular proliferation. Circulation 2001;104:1274-1279.
31. Nishimoto M, Takai S, Sawada Y, et al. Chymase-dependent angiotensin II formation in the saphenous vein versus the internal thoracic artery. J Thorac Cardiovasc Surg 2001;121:729-734.
32. Ohlstein EH, Romanic AM, Clark LV, et al. Application of in vivo and ex vivo magnetic resonance imaging for evaluation of tranilast on neointima formation following balloon angioplasty of the rat carotid artery. Cardiovasc Res 2000;47:759-768.
33. Okunishi H, Kawamoto T, Kurobe Y, et al. Pathogenetic role of vascular angiotensin-converting enzyme in the spontaneously hypertensive rat. Clin Exp Pharmacol Physiol 1991;18:649-659.
34. Peters S, Gotting B, Trummel M, Rust H, Brattstrom A. Valsartan for prevention of restenosis after stenting of type B2/C lesions: The VAL-PREST trial. J Invasive Cardiol 2001;13:93-97.
35. Powell JS, Clozel JP, Muler RKM, et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1991;245:186-188.
36. Roux SP. Clozel JP, Kuhn H. Cilazapril inhibits wall thickening of vein bypass graft in the rat. Hypertension 1991;18(Suppl 4):II43-II46.
37. Sasaki E, Tanahashi Y, Yamasaki Y, et al. Inhibitory effect of TAS-301, a new synthesized constrictive remodeling regulator, on renarrowing after balloon overstretch injury of porcine coronary artery. J Pharmacol Exp Ther 2000;295:1043-1050.
38. Sauvage LR, Wu HD, Kowalsky TE, et al. Healing basis and surgical techniques for complete revascularization of the left ventricle using only the internal mammary arteries. Ann Thorac Surg 1986;42:449-465.
39. Shiota N, Okunishi H, Takai S, et al. Tranilast suppresses vascular chymase expression and neointima formation in balloon-injured dog carotid artery. Circulation 1999;99:1084-1090.
40. Sukenaga Y, Kamoshita K, Takai S, Miyazaki M. Development of the chymase inhibitor as an anti-tissue-remodeling drug: Myocardial infarction and some other possibilities. Jpn J Pharmacol 2002;90:218-222.
41. Taipale J, Lohi J, Saarinen J, Kovanen PT, Keski-Oja J. Human mast cell chymase and leukocyte elastase release latent transforming growth factor-beta 1 from the extracellular matrix of cultured human epithelial and endothelial cells. J Biol Chem 1995;270:4689-4696.
42. Takai S, Jin D, Nishimoto M, et al. Oral administration of a specific chymase inhibitor, NK3201, inhibits vascular proliferation in grafted vein. Life Sci 2001;69:1725-1732.
43. Takai S, Jin D, Sakaguchi M, et al. A novel chymase inhibitor, BCEAB (4-[1-{[bis-(4-methyl-phenyl)-methyl]-carbamoyl}-3-(2-ethoxy-benzyl) -4-oxo-azetidine-2-yloxy]-benzoic acid) suppressed cardiac fibrosis in cardiomyopathic hamsters. J Pharmacol Exp Ther 2003;305:17-23.
44. Takai S, Jin D, Sakaguchi M, Miyazaki M. Chymase-dependent angiotensin II formation in human vascular tissue. Circulation 1999;100:654-658.
45. Takai S, Sakaguchi M, Jin D, Yamada M, Kirimura K, Miyazaki M. Different angiotensin II-forming pathways in human and rat vascular tissues. Clin Chim Acta 2001;305:191-195.
46. Takai S, Sakonjo H, Fukuda K, et al. A novel chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-[[, 4-dioxo-1-phenyl-7-(2-pyridyloxy)] 2-heptyl] acetamide (NK3201), suppressed intimal hyperplasia after balloon injury. J Pharmacol Exp Ther 2003;304:841-844.
47. Takai S, Shiota N, Jin D, Miyazaki M. Functional role of chymase in angiotensin II formation in human vascular tissue. J Cardiovasc Pharmacol 1998;32:826-833.
48. Takai S, Shiota N, Kobayashi S, Matsumura E, Miyazaki M. Induction of chymase that forms angiotensin II in the monkey atherosclerotic aorta. FEBS Lett 1997;412:86-90.
49. Takai S, Shiota N, Sakaguchi M, Muraguchi H, Matsumura E, Miyazaki M. Characterization of chymase from human vascular tissues. Clin Chim Acta 1997;265:13-20.
50. Takai S, Shiota N, Yamamoto D, Okunishi H, Miyazaki M. Purification and characterization of angiotensin II-generating chymase from hamster cheek pouch. Life Sci 1996;58:591-597.
51. Tamai H, Katoh O, Suzuki S, et al. Impact of tranilast on restenosis after coronary angioplasty: Tranilast restenosis following angioplasty trial (TREAT). Am Heart J 1999;138:968-975.
52. Taniyama Y, Morishita R, Nakagami H, et al. Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters. Circulation 2000;102:246-252.
53. Urschel HC, Miller ER, Razzuk MA, Alvares JF, McNamara JJ, Paulson DL. Aorta-to-coronary-artery vein bypass graft for coronary artery occlusive disease. Am Thorac Surg 1969;8:114-125.
54. Wang Y, Shiota N, Leskinen MJ, Lindstedt KA, Kovanen PT. Mast cell chymase inhibits smooth muscle cell growth and collagen expression in vitro: Transforming growth factor-beta 1-dependent and -independent effects. Arterioscler Thromb Vasc Biol 2001;21:1928-1933.
55. Wintroub BU, Schechter NM, Lazarus GS, Kaempfer CE, Schwartz LB. Angiotensin I conversion by human and rat chymotryptic protainases. J Invest Dermatol 1984;83:336-339.
56. Yuda A, Takai S, Jin D, et al. Angiotensin II receptor antagonist, L-158,809, prevents intimal hyperplasia in dog grafted veins. Life Sci 2000;68:41-48.
57. Zhang S, Anderson DF, Bradding P, et al. Human mast cells express stem cell factor. J Pathol 1998;186: 59-66.